In this strategy, tumor grade is regressed upon both the 4 clinicopathological covariates (ER status, PgR status, age and tumor size) and 430 gene expression levels, and significant predictor to tumor grade based on clinical covariates and genes are identified if they are retained in sparse regression analysis. This evidence concerns the gene PGR and neoplasm.